Apply Online for Pharmacovigilance Reporting Specialist at ICON plc

ICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. With our patients at the centre of all that we do, we help to accelerate the development of drugs and devices that save lives and improve quality of life. Our people are our greatest strength, are at the core of our culture, and the driving force behind our success.

Post : Pharmacovigilance Reporting Specialist

Job Description
• Preparing and submitting comprehensive safety reports, including periodic safety update reports (PSURs) and individual case safety reports (ICSRs), in compliance with regulatory standards.
• Conducting thorough data analysis to identify trends and assess the safety profile of pharmaceutical products.
• Collaborating with cross-functional teams to ensure timely and accurate reporting of adverse events.
• Maintaining up-to-date knowledge of pharmacovigilance regulations and industry best practices to ensure compliance.
• Providing training and support to team members on pharmacovigilance reporting processes and requirements.

Candidate Profile
• Bachelor's degree in a relevant scientific discipline or healthcare-related field
• Significant experience in pharmacovigilance reporting or drug safety within a clinical or pharmaceutical environment.
• Strong analytical skills with proficiency in data analysis tools and reporting software.
• Excellent communication and interpersonal skills, facilitating effective collaboration with internal and external stakeholders.
• A commitment to maintaining high standards of quality and compliance in all pharmacovigilance activities.

Additional Information
Qualification : Bachelor's degree
Location : Bangalore, Chennai, Trivandrum, Bengaluru
Industry Type : Pharma/ Healthcare/ Clinical research
Functional Area : Pharmacovigilance
End Date : 30th September 2026